Concepts (95)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Quantitative Structure-Activity Relationship | 3 | 2011 | 110 | 0.930 |
Why?
|
| Drug Discovery | 4 | 2014 | 108 | 0.930 |
Why?
|
| Gene Silencing | 2 | 2022 | 154 | 0.800 |
Why?
|
| Models, Molecular | 5 | 2011 | 876 | 0.690 |
Why?
|
| Rare Diseases | 1 | 2020 | 17 | 0.660 |
Why?
|
| Pharmaceutical Preparations | 2 | 2021 | 94 | 0.470 |
Why?
|
| RNA, Small Interfering | 2 | 2022 | 436 | 0.450 |
Why?
|
| Computer Simulation | 3 | 2011 | 408 | 0.400 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2011 | 127 | 0.380 |
Why?
|
| Receptors, Drug | 1 | 2011 | 61 | 0.350 |
Why?
|
| Estrogen Receptor beta | 1 | 2011 | 39 | 0.340 |
Why?
|
| Informatics | 1 | 2011 | 3 | 0.340 |
Why?
|
| Gene Library | 1 | 2011 | 62 | 0.340 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2010 | 18 | 0.320 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2010 | 33 | 0.320 |
Why?
|
| Drug Design | 1 | 2011 | 186 | 0.310 |
Why?
|
| Apoferritins | 1 | 2009 | 5 | 0.310 |
Why?
|
| Computer Graphics | 1 | 2009 | 18 | 0.300 |
Why?
|
| Anesthetics | 1 | 2009 | 11 | 0.300 |
Why?
|
| User-Computer Interface | 1 | 2009 | 74 | 0.290 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2020 | 161 | 0.280 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2008 | 97 | 0.270 |
Why?
|
| Computational Biology | 1 | 2010 | 327 | 0.260 |
Why?
|
| Ligands | 3 | 2011 | 388 | 0.230 |
Why?
|
| PubMed | 2 | 2020 | 5 | 0.210 |
Why?
|
| Hedgehog Proteins | 1 | 2024 | 54 | 0.200 |
Why?
|
| Pyridines | 1 | 2024 | 139 | 0.200 |
Why?
|
| Pyrimidines | 1 | 2024 | 139 | 0.200 |
Why?
|
| Nucleotides | 1 | 2022 | 37 | 0.190 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 1081 | 0.190 |
Why?
|
| RNA Interference | 1 | 2022 | 247 | 0.180 |
Why?
|
| Autophagy | 2 | 2020 | 140 | 0.170 |
Why?
|
| Algorithms | 3 | 2021 | 509 | 0.160 |
Why?
|
| Semantics | 1 | 2020 | 29 | 0.160 |
Why?
|
| Fatty Liver | 1 | 2020 | 77 | 0.150 |
Why?
|
| Oncogenes | 1 | 2018 | 44 | 0.140 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 259 | 0.140 |
Why?
|
| Binding Sites | 2 | 2011 | 671 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 220 | 0.140 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2020 | 220 | 0.140 |
Why?
|
| RNA, Messenger | 1 | 2022 | 1271 | 0.140 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2020 | 163 | 0.140 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2018 | 165 | 0.130 |
Why?
|
| Models, Biological | 2 | 2011 | 712 | 0.130 |
Why?
|
| Liver Neoplasms | 1 | 2020 | 224 | 0.130 |
Why?
|
| Molecular Structure | 2 | 2009 | 570 | 0.130 |
Why?
|
| Protein Binding | 2 | 2011 | 1082 | 0.130 |
Why?
|
| Antineoplastic Agents | 2 | 2024 | 1019 | 0.120 |
Why?
|
| Humans | 9 | 2024 | 43102 | 0.110 |
Why?
|
| Insulin-Secreting Cells | 1 | 2014 | 28 | 0.110 |
Why?
|
| Endoplasmic Reticulum | 1 | 2014 | 108 | 0.100 |
Why?
|
| Animals | 6 | 2024 | 16992 | 0.100 |
Why?
|
| Least-Squares Analysis | 1 | 2010 | 45 | 0.080 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2010 | 99 | 0.080 |
Why?
|
| Principal Component Analysis | 1 | 2010 | 87 | 0.080 |
Why?
|
| Horses | 1 | 2009 | 28 | 0.080 |
Why?
|
| Artificial Intelligence | 1 | 2011 | 112 | 0.070 |
Why?
|
| ROC Curve | 1 | 2009 | 159 | 0.070 |
Why?
|
| Molecular Conformation | 1 | 2009 | 155 | 0.070 |
Why?
|
| Crystallography, X-Ray | 1 | 2009 | 280 | 0.070 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2008 | 8 | 0.070 |
Why?
|
| Thymidine Kinase | 1 | 2008 | 9 | 0.070 |
Why?
|
| HIV Protease | 1 | 2008 | 23 | 0.070 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2008 | 35 | 0.070 |
Why?
|
| X-Ray Diffraction | 1 | 2008 | 66 | 0.070 |
Why?
|
| Protein Conformation | 1 | 2009 | 416 | 0.070 |
Why?
|
| Databases, Factual | 1 | 2009 | 341 | 0.070 |
Why?
|
| Neoplasms | 1 | 2018 | 1377 | 0.070 |
Why?
|
| Structure-Activity Relationship | 1 | 2009 | 506 | 0.070 |
Why?
|
| Receptors, Estrogen | 1 | 2008 | 183 | 0.060 |
Why?
|
| Mice | 3 | 2024 | 6644 | 0.060 |
Why?
|
| Time Factors | 1 | 2009 | 1857 | 0.050 |
Why?
|
| NIH 3T3 Cells | 1 | 2024 | 64 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2024 | 2157 | 0.050 |
Why?
|
| Knowledge | 1 | 2021 | 16 | 0.040 |
Why?
|
| Pattern Recognition, Automated | 1 | 2021 | 32 | 0.040 |
Why?
|
| Cell Survival | 1 | 2024 | 945 | 0.040 |
Why?
|
| Data Mining | 1 | 2020 | 30 | 0.040 |
Why?
|
| Female | 1 | 2020 | 24698 | 0.040 |
Why?
|
| Neoplasms, Experimental | 1 | 2018 | 38 | 0.040 |
Why?
|
| Transplantation, Heterologous | 1 | 2018 | 98 | 0.040 |
Why?
|
| Transfection | 1 | 2020 | 532 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2018 | 200 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 237 | 0.030 |
Why?
|
| Drosophila melanogaster | 1 | 2018 | 193 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2024 | 2676 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2018 | 384 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 307 | 0.030 |
Why?
|
| High-Throughput Screening Assays | 1 | 2014 | 74 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2020 | 1455 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2020 | 2544 | 0.030 |
Why?
|
| Apoptosis | 1 | 2018 | 1568 | 0.020 |
Why?
|
| Rats | 1 | 2014 | 3735 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 760 | 0.020 |
Why?
|
| Male | 1 | 2020 | 23409 | 0.010 |
Why?
|